Oncopeptides Chief Financial Officer Holger Lembrer takes office today

Oncopeptides AB announced that Holger Lembrer has taken office as Chief Financial Officer (CFO) as of January 18, 2023.

Rhea-AI Summary

Oncopeptides AB announced that Holger Lembrer has taken office as Chief Financial Officer (CFO) as of January 18, 2023. His appointment aims to enhance the company’s leadership team, bringing valuable expertise from his previous roles in publicly traded international companies. Oncopeptides focuses on developing therapies for difficult-to-treat hematological diseases, leveraging its proprietary Peptide Drug Candidate platform. Pepaxti, their notable product, has received marketing authorization in the EU and other regions for the treatment of adult patients with multiple myeloma, although it is not currently marketed in the US following a recommendation to withdraw its authorization.

Positive

• Appointment of Holger Lembrer as CFO may enhance financial strategy and operations.
• Pepaxti has received marketing authorization in the EU and other regions, indicating product acceptance.

Negative

• Pepaxto's US marketing authorization was recommended for withdrawal by the FDA, reflecting regulatory challenges.

Argus Session date unavailable

+2.54% session move Open Argus

Details

News Market Reaction – ONCO

The recorded move for ONCO in the trading session of this news was +2.54%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, Jan. 18, 2023 /PRNewswire/ -- Oncopeptides AB (publ.) (NASDAQ Stockholm: ONCO), a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat hematological diseases, today announces that Holger Lembrer, who recently was appointed Chief Financial Officer, CFO, takes the office on January 18.

"I am very pleased that Holger Lembrer assumes his position today, and really look forward to working together with him," says Monica Shaw, CEO of Oncopeptides. "His combined expertise from leading financial roles, in a highly recognized, publicly traded, international Company, will be a great asset for Oncopeptides and its Leadership Team."

For more information, please contact:

Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB (publ.)
E-mail: rolf.gulliksen@oncopeptides.com
Cell phone: + 46 70 262 96 28

The information was submitted for publication, through the agency of the contact person above on January 18, 2023, at 08:00 (CET).

About Oncopeptides

Oncopeptides is a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform, PDC, to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. 

Pepaxti^® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto^®. The drug is currently not marketed in the US. On December 7, 2022, the FDA recommended that the Company voluntarily withdraw the US marketing authorization for Pepaxto.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on NASDAQ Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com. 

The following files are available for download:

https://mb.cision.com/Main/15404/3699254/1787726.pdf

Oncopeptides Chief Financial Officer Holger Lembrer takes office today

 

View original content:https://www.prnewswire.com/news-releases/oncopeptides-chief-financial-officer-holger-lembrer-takes-office-today-301724362.html

SOURCE Oncopeptides AB

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When did Holger Lembrer become CFO of Oncopeptides?

Holger Lembrer took office as CFO on January 18, 2023.

What is the focus of Oncopeptides?

Oncopeptides focuses on developing therapies for difficult-to-treat hematological diseases.

What is Pepaxti and where is it authorized?

Pepaxti is a treatment for multiple myeloma and has marketing authorization in the EU and other regions.

Why is Pepaxto not marketed in the US?

Pepaxto is not marketed in the US following an FDA recommendation to voluntarily withdraw its marketing authorization.